Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$59.10
-2.4%
$61.38
$54.48
$94.93
$8.01B1.191.14 million shs1.81 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$76.85
+0.8%
$69.41
$55.30
$94.99
$3.69B0.39673,113 shs249,556 shs
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$13.49
-0.3%
$13.18
$11.06
$32.66
$1.05B1.15973,046 shs759,134 shs
Nevro Corp. stock logo
NVRO
Nevro
$5.85
+0.1%
$5.85
$3.17
$10.37
$224.32M0.81800,223 shs753,602 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$17.06
-0.1%
$20.53
$15.75
$48.24
$1.12B1.481.48 million shs1.10 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.00%+0.96%-0.60%-14.36%-13.84%
Haemonetics Corporation stock logo
HAE
Haemonetics
0.00%+3.89%+9.07%+26.40%-8.71%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
0.00%+9.72%+1.47%-31.09%-53.06%
Nevro Corp. stock logo
NVRO
Nevro
0.00%0.00%0.00%0.00%-30.24%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.00%-9.90%-17.41%+1.09%-57.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.9493 of 5 stars
4.35.00.04.12.52.51.9
Haemonetics Corporation stock logo
HAE
Haemonetics
4.8712 of 5 stars
4.52.00.04.32.41.72.5
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4.0836 of 5 stars
2.91.00.04.01.41.72.5
Nevro Corp. stock logo
NVRO
Nevro
0.171 of 5 stars
1.00.00.00.00.01.70.6
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.2905 of 5 stars
4.21.00.04.93.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.62
Moderate Buy$94.0059.05% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.91
Moderate Buy$96.8025.97% Upside
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
1.78
Reduce$18.6338.12% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$5.36-8.29% Downside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.40
Hold$33.4395.90% Upside

Current Analyst Ratings Breakdown

Latest HAE, NVRO, TNDM, IART, and GMED Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$24.00
6/10/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/22/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/12/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$80.00 ➝ $68.00
5/9/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $80.00
5/9/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $105.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.51B3.19$6.65 per share8.89$30.40 per share1.94
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.71$7.20 per share10.67$16.34 per share4.70
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$1.61B0.65$4.45 per share3.03$20.03 per share0.67
Nevro Corp. stock logo
NVRO
Nevro
$408.52M0.55N/AN/A$8.10 per share0.72
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$940.20M1.21N/AN/A$4.01 per share4.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$102.98M$1.3444.1014.671.727.39%10.52%8.56%8/5/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3123.2215.251.2512.32%26.37%9.22%8/14/2025 (Estimated)
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
-$6.94M-$0.38N/A5.390.75-1.78%12.12%4.58%8/4/2025 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)

Latest HAE, NVRO, TNDM, IART, and GMED Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.74$0.68-$0.06$0.54$629.74 million$598.12 million
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
5/5/2025Q1 2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$0.43$0.41-$0.02-$0.33$381.17 million$382.65 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.45
2.72
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
0.81
1.21
0.72
Nevro Corp. stock logo
NVRO
Nevro
0.67
5.02
3.76
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.99
2.30
1.81

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
84.78%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.51%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
3.54%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,300135.38 million110.32 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4,39677.71 million74.96 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,09038.37 million36.27 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65066.61 million65.34 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Globus Medical stock logo

Globus Medical NYSE:GMED

$59.10 -1.47 (-2.43%)
Closing price 07/3/2025 03:34 PM Eastern
Extended Trading
$59.10 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics stock logo

Haemonetics NYSE:HAE

$76.84 +0.61 (+0.79%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$76.84 0.00 (0.00%)
As of 07/3/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Integra LifeSciences stock logo

Integra LifeSciences NASDAQ:IART

$13.48 -0.04 (-0.26%)
Closing price 07/3/2025 02:35 PM Eastern
Extended Trading
$13.48 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Nevro stock logo

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$17.06 -0.02 (-0.09%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$16.72 -0.34 (-2.02%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.